Vericel Corp Company Profile (NASDAQ:VCEL)

About Vericel Corp (NASDAQ:VCEL)

Vericel Corp logoVericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VCEL
  • CUSIP: N/A
  • Web:
  • Market Cap: $90.11 million
  • Outstanding Shares: 32,766,000
Average Prices:
  • 50 Day Moving Avg: $2.63
  • 200 Day Moving Avg: $2.72
  • 52 Week Range: $1.96 - $4.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $49.64 million
  • Price / Sales: 1.82
  • Book Value: $0.47 per share
  • Price / Book: 5.85
  • EBIDTA: ($22,390,000.00)
  • Net Margins: -34.31%
  • Return on Assets: -52.60%
  • Current Ratio: 1.37%
  • Quick Ratio: 1.14%
  • Average Volume: 265,668 shs.
  • Beta: 2.85
  • Short Ratio: 3.22

Frequently Asked Questions for Vericel Corp (NASDAQ:VCEL)

What is Vericel Corp's stock symbol?

Vericel Corp trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel Corp's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) released its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.12. The company had revenue of $9.36 million for the quarter. View Vericel Corp's Earnings History.

Where is Vericel Corp's stock going? Where will Vericel Corp's stock price be in 2017?

2 equities research analysts have issued 1 year price objectives for Vericel Corp's shares. Their predictions range from $6.00 to $6.00. On average, they expect Vericel Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Vericel Corp.

Are investors shorting Vericel Corp?

Vericel Corp saw a decline in short interest in April. As of April 13th, there was short interest totalling 1,722,949 shares, a decline of 4.7% from the March 31st total of 1,808,420 shares. Based on an average daily trading volume, of 244,386 shares, the short-interest ratio is presently 7.1 days.

Who are some of Vericel Corp's key competitors?

Who owns Vericel Corp stock?

Vericel Corp's stock is owned by a number of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (9.98%), Vanguard Group Inc. (3.44%), Perkins Capital Management Inc. (0.70%), Geode Capital Management LLC (0.67%), Renaissance Technologies LLC (0.25%) and KCG Holdings Inc. (0.14%). View Institutional Ownership Trends for Vericel Corp.

Who sold Vericel Corp stock? Who is selling Vericel Corp stock?

Vericel Corp's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and KCG Holdings Inc.. View Insider Buying and Selling for Vericel Corp.

Who bought Vericel Corp stock? Who is buying Vericel Corp stock?

Vericel Corp's stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Vericel Corp.

How do I buy Vericel Corp stock?

Shares of Vericel Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vericel Corp stock cost?

One share of Vericel Corp stock can currently be purchased for approximately $2.75.

Analyst Ratings

Consensus Ratings for Vericel Corp (NASDAQ:VCEL) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (118.18% upside)

Analysts' Ratings History for Vericel Corp (NASDAQ:VCEL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/13/2017Needham & Company LLCReiterated RatingBuy -> Buy$9.00 -> $6.00HighView Rating Details
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$6.00N/AView Rating Details
4/5/2016Bank of America CorpDowngradeBuy -> NeutralN/AView Rating Details
3/12/2016Ladenburg Thalmann Financial ServicesReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Vericel Corp (NASDAQ:VCEL)
Earnings by Quarter for Vericel Corp (NASDAQ:VCEL)
Earnings History by Quarter for Vericel Corp (NASDAQ:VCEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.19)($0.31)$9.36 millionViewN/AView Earnings Details
11/7/2016Q3($0.28)($0.38)$10.93 millionViewListenView Earnings Details
5/10/2016Q116($0.25)($0.08)$11.60 million$14.10 millionViewListenView Earnings Details
3/14/2016Q415($0.15)($0.28)$17.36 million$15.40 millionViewListenView Earnings Details
11/13/2015Q315($0.21)($0.26)$10.50 million$11.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.16)$11.31 million$13.60 millionViewListenView Earnings Details
5/14/2015Q115($0.14)($0.27)$11.10 million$10.80 millionViewListenView Earnings Details
3/23/2015Q414($0.47)($0.17)$10.70 million$14.70 millionViewListenView Earnings Details
11/13/2014Q314($0.66)($0.52)$6.73 million$9.66 millionViewN/AView Earnings Details
8/14/2014Q214($1.59)($0.94)$2.50 million$4.43 millionViewN/AView Earnings Details
5/15/2014Q114($0.92)($1.26)ViewN/AView Earnings Details
3/13/2014Q413($1.34)($0.97)$0.02 million$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($2.02)($0.06)ViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vericel Corp (NASDAQ:VCEL)
Current Year EPS Consensus Estimate: $-0.80 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS


Dividend History for Vericel Corp (NASDAQ:VCEL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vericel Corp (NASDAQ:VCEL)
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 24.31%
Insider Trades by Quarter for Vericel Corp (NASDAQ:VCEL)
Institutional Ownership by Quarter for Vericel Corp (NASDAQ:VCEL)
Insider Trades by Quarter for Vericel Corp (NASDAQ:VCEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2016Consonance Capital ManagementMajor ShareholderSell120,000$5.39$646,800.00View SEC Filing  
9/16/2014Daniel OrlandoCOOBuy9,804$2.55$25,000.20View SEC Filing  
9/16/2014Dominick ColangeloCEOBuy20,000$2.55$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vericel Corp (NASDAQ:VCEL)
Latest Headlines for Vericel Corp (NASDAQ:VCEL)
DateHeadline logoEdited Transcript of VCEL earnings conference call or presentation 10-May-17 12:00pm GMT - May 12 at 3:44 AM logoVericel Corp (VCEL) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - May 11 at 4:26 PM logoVericel's (VCEL) CEO Nick Colangelo on Q1 2017 Results - Earnings Call Transcript - May 11 at 3:03 AM logoVericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia - May 10 at 10:00 AM logoVericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy - May 10 at 10:00 AM logoVericel Reports First-Quarter 2017 Financial Results - May 10 at 10:00 AM logoInvestor Network: Vericel Corporation to Host Earnings Call - May 10 at 10:00 AM logoVericel Corp (VCEL) Expected to Announce Earnings of -$0.19 Per Share - May 8 at 1:12 PM logoVericel Corp (VCEL) Scheduled to Post Quarterly Earnings on Monday - May 6 at 7:04 AM logoVericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017 - May 5 at 3:10 AM logoVericel Corp (VCEL) Getting Somewhat Negative Press Coverage, Report Shows - April 30 at 9:04 AM logoShort Interest in Vericel Corp (VCEL) Drops By 4.7% - April 29 at 7:18 PM logoVericel to Present at the 5th Annual Cell & Gene Therapy Investor Day - GlobeNewswire (press release) - April 21 at 8:30 PM logo Analysts Anticipate Vericel Corp (VCEL) to Post -$0.19 Earnings Per Share - April 17 at 3:06 PM logoVericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs - April 10 at 8:00 PM logoETFs with exposure to Vericel Corp. : April 7, 2017 - April 7 at 6:21 PM logoVericel to Present at the 16th Annual Needham Healthcare Conference - March 28 at 8:29 AM logoOutcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association - March 23 at 3:50 PM logoVericel Corp’s (VCEL) “Buy” Rating Reiterated at Needham & Company LLC - March 17 at 9:29 AM logoVericel Corp (VCEL) Gains Despite Projected Loss - March 11 at 11:33 PM logoVericel's (VCEL) CEO Nick Colangelo on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha - March 11 at 9:58 AM logoVericel Reports Fourth-Quarter and Year-End 2016 Financial Results - March 10 at 10:08 AM logoVERICEL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 10 at 10:08 AM logoVericel (VCEL) Presents At Cowen and Company 37th Annual Health Care Conference - Slideshow - March 9 at 4:10 AM logoVericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017 - March 3 at 8:22 AM logoBiotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen - March 1 at 9:02 AM logoVericel to Present at Multiple Upcoming Investor Conferences - February 27 at 5:19 PM logoVericel (VCEL) Announces Receipt of FDA Fast Track Designation for Ixmyelocel-T - February 21 at 4:25 PM logoVericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy - February 21 at 4:25 PM logo7:31 am Vericel: FDA has designated the investigation of ixmyelocelT for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Trac - February 21 at 4:25 PM logoVericel (VCEL) Reports First MACI Implant in U.S. for Treatment of Symptomatic Cartilage Defects of the Knee - - February 2 at 6:32 AM logo7:02 am Vericel announces the first implant of MACI in the US for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults - February 2 at 6:32 AM logoVericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee - February 1 at 7:17 AM logoVERICEL CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - January 4 at 7:33 AM logoCoverage initiated on Vericel by Piper Jaffray - December 23 at 3:46 AM logoVericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $20 Million Offering of Common Stock - December 21 at 8:24 PM



Vericel Corp (VCEL) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff